Navigation Links
Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Date:8/11/2008

CALGARY, Aug. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with docetaxel (Taxotere(R)) in patients with advanced cancers including bladder, prostate, lung and upper gastro-intestinal. The principal investigator is Professor Hardev Pandha of the Royal Surrey Hospital, U.K.

The trial (REO 010) has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with docetaxel every three weeks. Standard dosages of docetaxel were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a further nine patients at the top dose of REOLYSIN(R) in combination with a standard dosage of docetaxel.

"We have completed the dose escalation stage of the study," said Prof. Pandha. "Patients enrolled had previously undergone significant treatment with combination chemotherapy. The combination of REOLYSIN(R) and taxotere was safe, well tolerated with no obvious toxicity related specifically to REOLYSIN(R). Efficacy of the combination was encouraging: both objective anti-tumour responses and disease stabilization were observed radiologically."

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including bladder, lung, prostate or upper gastro-intestinal cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with docetaxel. Secondary objectives include the evaluation of immune resp
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Longmeadow, Mass. (PRWEB) April 28, 2015 ... of outsourced medical device manufacturing services for complex ... devices , today announced plans to develop a ... Enfield, Conn. , CIRTEC has a long ... most innovative startups to usher breakthrough neurostimulation, heart ...
(Date:4/28/2015)... drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) ... NASDAQ informing it that it had regained full compliance ... In November 2014, the Company received a deficiency ... plan to regain compliance with the Listing Rule, which ... equity as of June 30, 2014; (ii) at least ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 More than ... psychosis at some point over the course of their ... symptoms that worsen as the disease progresses. ReachMD ... announces the launch of a series dedicated to PD ... in PD, movement disorders, and psychiatric conditions. , The ...
(Date:4/28/2015)... 28, 2015 First Harvest Financial ... leading source for advice to legal medical cannabis companies. ... and strategic planning to start-ups and entrepreneurs, First Harvest ... industry. , Wall Street veteran, Kevin Gillespie, has ... President and Portfolio Manager. Due to early success ...
Breaking Biology Technology:CIRTEC Medical Systems Expands Capacity with New Advanced Manufacturing Facility 2Novogen Regains Full Compliance with NASDAQ Listing Rule 2Novogen Regains Full Compliance with NASDAQ Listing Rule 3ReachMD Launches Series Focusing on Parkinson’s Disease Psychosis 2Leading Medical Cannabis Advisor, First Harvest Financial, Welcomes Top Executives Aboard 2Leading Medical Cannabis Advisor, First Harvest Financial, Welcomes Top Executives Aboard 3
... Israel, October 4, 2010 ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... Culex quinquefasciatus mosquito poses a significant threat ... worms and encephalitis-inducing viruses. An international team of scientists, ... SIB Swiss Institute of Bioinformatics sequenced its genome and ... in today,s issue of Science, describe results from comparing ...
... PHILADELPHIA, Oct. 1 Kibow has recently completed a ... a limited number of patients in USA, Canada, Argentina ... just been published in the September issue of the ... Study of Probiotic Dietary Supplementation for Promoting Health Kidney ...
Cached Biology Technology:EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 2EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 3EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 4EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 5EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 6EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 7Major disease-vector mosquito reveals the secrets of its immune system 2Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health 2Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health 3
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... to clean energy needs to be reformed if it ... according to two new articles by Stanford writers. ... massive energy system comes amid taxpayers, $500 million tab ... Solyndra, the global recession, government budget cuts and plunging ...
... and the Max Planck Institute for Evolutionary Anthropology have ... of Congo seem to be more successful than smaller ... The studyconducted over a 12-year period in Nouabal-Ndoki National ... selective pressures that influence the evolution of great apes. ...
... 1, 2012)A recent study published in the May/June 2012 ... journal of the Academy of General Dentistry, found that ... energy drinks, especially among adolescents, is causing irreversible damage ... erode tooth enamel, the glossy outer layer of the ...
Cached Biology News:America's clean energy policies need a reality check, say Stanford researchers 2America's clean energy policies need a reality check, say Stanford researchers 3America's clean energy policies need a reality check, say Stanford researchers 4Bigger gorillas better at attracting mates and raising young 2Sports and energy drinks responsible for irreversible damage to teeth 2
... 5-OxoETE-d7 is used as an internal ... stable isotope dilution mass spectrometry. 5-OxoETE is ... oxidation of 5-HETE in human neutrophils. It ... an EC50 of 2 nM. 5-OxoETE selectively ...
BD BioCoat Osteologic Coverslips that have been sterilized by ETO gas. Coating : Osteologic&trade ,Thickness : 0.16 mm ,Diameter : 12.7 mm ,Gridded : No ...
... solid. A nucleoside antibiotic that inhibits ... of N-glycosidic protein-carbohydrate linkages. Active ... yeasts, fungi, and viruses. Inhibits the ... human T-lymphoblastoid cells. Also inhibits thrombin-induced ...
... 120 V, is used for agitation and mixing ... staining and destaining of gels and blots, and ... (8-40 rpm) and can handle a maximum load ... two 29 x 21 cm platforms covered with ...
Biology Products: